Nasdaq
$806.92▲ 0.23%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $84.60BShares out 100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 10.15After-hours26.10.16 05:024Ownership#●●●
REGENERON PHARMACEUTICALS, INC.
Andrew J. Murphy, an executive at Regeneron Pharmaceuticals, reported a change in beneficial ownership of company securities effective October 13, 2026. This filing serves as a Form 4 statement regarding insider stock holdings.…more
$806.92+0.23%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14After-hours26.10.15 05:04144Ownership
REGENERON PHARMACEUTICALS, INC.
Andrew J. Murphy, an insider at Regeneron Pharmaceuticals, Inc., has filed an SEC Form 144 to report the proposed sale of company shares. This filing represents a standard procedure for an insider disposing of their holdings.…more
$806.92+0.23%vs prev closeView filingShare - 10.6Pre-market26.10.06 20:518-KKey event
REGENERON PHARMACEUTICALS, INC.
Regeneron has amended its existing license and collaboration agreement with Sanofi to co-develop and co-commercialize four new antibody therapies. Under the terms, Regeneron will receive a $1 billion upfront payment and is eligible for up to $7 billion in additional development and commercial milestones. Additionally, the company expects a $22 million pre-tax IPR&D charge in Q3 2026, which is projected to reduce GAAP and non-GAAP EPS by approximately $0.18.…more
$806.92+0.23%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4h agoClosed26.10.25 18:15#●●●#●●●
Regeneron's Libtayo Shows Sustained Long-Term Survival Benefit in CSCC
Regeneron announced that long-term data from its Phase 3 C-POST trial demonstrate a clinically meaningful overall survival benefit for Libtayo as an adjuvant treatment in high-risk cutaneous squamous cell carcinoma. These findings reinforce the drug's role as a standard of care following nearly four years of follow-up.…more
$806.92+0.23%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.16Pre-market26.10.16 20:00
●●●●●●●● ●●●●● ●●●●●●
Regeneron's cancer therapy Libtayo has received a positive opinion from the CHMP for an extended dosing schedule and reduced infusion time in the EU. While this improvement enhances patient convenience and potential market competitiveness, it does not represent a direct increase in financial performance.…more
$806.92+0.23%vs prev close - 10.12Regular26.10.13 02:34
●●●●●●●● ●●●●● ●●●●●●
Regeneron's Phase 3 trial for its FOP drug Pasatru demonstrated sustained efficacy in halting abnormal bone growth through 84 weeks. These results reinforce the clinical profile of the recently FDA-approved treatment and support plans to expand trials to pediatric patients.…more
$806.92+0.23%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report